We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
-$115M
Cap. Flow
-$85.2M
Cap. Flow %
-17.03%
Top 10 Hldgs %
48.26%
Holding
330
New
47
Increased
56
Reduced
65
Closed
116

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$14.3M
2
IKT icon
Inhibikase Therapeutics
IKT
+$12.7M
3
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$10.1M
4
ABVX
Abivax
ABVX
+$9.13M
5
RVMD icon
Revolution Medicines
RVMD
+$6.34M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$27.8M
2
CYTK icon
Cytokinetics
CYTK
+$25.8M
3
KROS icon
Keros Therapeutics
KROS
+$21.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$19.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.69%
2 Financials 3.07%
3 Communication Services 1.32%
4 Technology 0.33%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
126
Ultragenyx Pharmaceutical
RARE
$2.52B
$337K 0.07%
+8,000
New +$397K
BMRN icon
127
CALL
BioMarin Pharmaceuticals
BMRN
$12.2B
$329K 0.07%
5,000
– –
JVSA
128
DELISTED
JV SPAC Acquisition Corp
JVSA
$313K 0.06%
30,000
– –
TSHA icon
129
Taysha Gene Therapies
TSHA
$1.84B
$307K 0.06%
177,707
-73,693
-29% -$153K
CYPH
130
Cypherpunk Technologies Inc
CYPH
$73.5M
$305K 0.06%
+106,000
New +$315K
ACLX
131
DELISTED
Arcellx
ACLX
$304K 0.06%
3,962
– –
KALV
132
DELISTED
KalVista Pharmaceuticals
KALV
$304K 0.06%
35,843
+21,700
+153% +$225K
ALKS icon
133
Alkermes
ALKS
$8.23B
$293K 0.06%
10,188
-64,243
-86% -$1.85M
EXAS
134
DELISTED
Exact Sciences
EXAS
$281K 0.06%
5,000
-10,200
-67% -$635K
TARS icon
135
CALL
Tarsus Pharmaceuticals
TARS
$2.8B
$277K 0.06%
5,000
– –
VTYX
136
DELISTED
Ventyx Biosciences
VTYX
$273K 0.05%
124,530
+26,575
+27% +$60.2K
ALVO icon
137
Alvotech
ALVO
$1.28B
$273K 0.05%
+20,600
New +$254K
WVE icon
138
Wave Life Sciences
WVE
$1.17B
$268K 0.05%
+21,700
New +$290K
GOSS icon
139
Gossamer Bio
GOSS
$87.2M
$267K 0.05%
295,613
-121,345
-29% -$104K
QNCX icon
140
Quince Therapeutics
QNCX
$29.5M
$267K 0.05%
715
– –
IRON icon
141
Disc Medicine
IRON
$2.97B
$266K 0.05%
4,196
-18,368
-81% -$1.06M
BCRX icon
142
BioCryst Pharmaceuticals
BCRX
$2.41B
$263K 0.05%
35,000
– –
UCFI
143
CN Healthy Food Tech Group
UCFI
$257K 0.05%
25,000
– –
RNXT icon
144
RenovoRx
RNXT
$50.1M
$254K 0.05%
197,250
-117,942
-37% -$134K
PYPD icon
145
PolyPid
PYPD
$93M
$243K 0.05%
80,080
-13,822
-15% -$45.4K
MRK icon
146
Merck
MRK
$316B
$243K 0.05%
2,440
+1,300
+114% +$134K
ARWR icon
147
Arrowhead Research
ARWR
$12.3B
$243K 0.05%
12,900
+1,195
+10% +$24.6K
KOD icon
148
Kodiak Sciences
KOD
$2.84B
$236K 0.05%
+23,700
New +$136K
TXMD icon
149
TherapeuticsMD
TXMD
$24.1M
$232K 0.05%
270,160
– –
TENX icon
150
Tenax Therapeutics
TENX
$522M
$215K 0.04%
34,693
-27,730
-44% -$135K
4 5
6
7 8

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, ADAR1 Capital Management held 330 positions worth $500M, down 19% from $615M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management withdrew a net $85.2M in Q4 2024, closing 116 positions and reducing 65 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 86% a quarter earlier, followed by Financials and Communication Services.

Against the trend, ADAR1 Capital Management opened a new position in Inhibikase Therapeutics worth $16.6M.

  • ADAR1 Capital Management's largest Q4 2024 buy was Inhibikase Therapeutics: 5,103,005 shares worth $16.6M.
  • ADAR1 Capital Management added most to Zai Lab in Q4 2024, an estimated $14.3M increase.
  • ADAR1 Capital Management's biggest Q4 2024 reduction was Royalty Pharma, cutting an estimated $27.8M.
  • ADAR1 Capital Management fully exited Syndax Pharmaceuticals in Q4 2024, selling an estimated $6.74M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $500M portfolio in Q4 2024.
  • ADAR1 Capital Management opened 47 new positions and closed 116 in Q4 2024.
  • ADAR1 Capital Management's portfolio value fell 19% quarter-over-quarter to $500M.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.